RARX Ra Pharmaceuticals Inc.

-0.09  -0%
Previous Close 20.05
Open 20
Price To Book 8.05
Market Cap 646664599
Shares 32,398,026
Volume 107,908
Short Ratio
Av. Daily Volume 544,732

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial met endpoints - December 10, 2018. Phase 3 planned.
RA101495 zilucoplan
Myasthenia Gravis (MG)
Phase 3 trial to be initiated 1H 2019.
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 1b PK data released September 26, 2018.
RA101495 SC
Atypical hemolytic uremic syndrome (aHUS)

Latest News

  1. Hedge Funds Are Betting On Ra Pharmaceuticals, Inc. (RARX)
  2. Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock
  3. The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings
  4. Why Nutrisystem, Xperi, and Ra Pharmaceuticals Jumped Today
  5. Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock
  6. Here's Why Ra Pharmaceuticals Inc. Is Soaring Today
  7. Ra Pharma Shares Rally: What You Need To Know
  8. Ra Pharmaceuticals Announces Positive Top-line Data from Phase 2 Trial of Zilucoplan in Patients with Generalized Myasthenia Gravis
  9. Ra Pharmaceuticals Receives Development Milestone Payment Under Agreement with Merck
  10. Ra Pharmaceuticals Elects Bo Cumbo to Board of Directors
  11. ADDING and REPLACING Ra Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
  12. Ra Pharmaceuticals to Present at Upcoming Investor Conferences
  13. Can the Rally in Ra Pharmaceuticals (RARX) Shares Continue?
  14. Ra Pharma Announces Positive Results from Phase 1b Pharmacokinetic Study of Zilucoplan (RA101495 SC) in Patients with Renal Impairment
  15. Ra Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference
  16. Ra Pharma Elects Aoife M. Brennan, M.B., B.Ch., to Board of Directors
  17. Ra Pharma Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Phase 3 PNH Program
  18. Ra Pharmaceuticals Reports Second Quarter 2018 Financial Results and Announces Early Completion of Enrollment in gMG Phase 2 Program
  19. Ra Pharmaceuticals Presents Data on Oral, Small Molecule Complement Inhibitors and Phase 2 RA101495 SC Program in PNH at the 23rd Congress of the European Hematology Association